Peanut Allergy Patch Gets FDA Review
- French biotech DBV to file for U.S. approval in second half
- Novel Viaskin therapy missed a key target in a recent study
Photographer: Dhiraj Singh/Bloomberg
This article is for subscribers only.
French biotechnology company DBV Technologies SA got permission to seek U.S. Food and Drug Administration approval to sell its experimental peanut-allergy patch, reassuring investors about the product’s prospects.
The FDA “agreed that the available efficacy and safety data” supports the submission of an application that, if approved, would let DBV bring its Viaskin patch to market, the Bagneux, France-based company said. The stock had its biggest gain on record.